Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.
Helmut ButzkuevenTomas KalincikFrancesco PattiMark SleeBianca Weinstock-GuttmanKatherine BuzzardOlga SkibinaRaed AlroughaniAlexandre PratMarc GirardDana HorakovaEva Kubala HavrdovaAnneke Van Der WaltSara EichauRobert HydeNolan CampbellKarthik BodhinathanTim Spelmannull nullPublished in: Therapeutic advances in neurological disorders (2024)
Early initiation of natalizumab produced long-term benefits in relapse outcomes in comparison with BRACETD, regardless of a subsequent escalation in therapy.